Lupin has launched a new diabetes drug in the United States, strengthening its presence in regulated markets. The launch is expected to contribute positively to revenue growth.
The company continues to focus on complex generics and specialty drugs to improve margins. Expansion in the US market remains a key pillar of its long-term strategy.
With increasing global demand for healthcare solutions, Lupin is well-positioned to capitalize on growth opportunities in the pharmaceutical sector.
